Incyte Corporation

Valuation Analysis

About the Company

Incyte Corporation en bref

Incyte Corporation (INCY) is currently trading at 85,62 € with a market capitalization of 17,1 Md €. The trailing P/E ratio stands at 13.87x, with a forward P/E of 10.72x. The 52-week range spans from 58,18 € to 97,89 €; the current price is 12.5% below the yearly high. Year-over-year revenue growth stands at +20.9%. The net profit margin stands at 26.71%.

💰 Dividende

Incyte Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

23 analystes évaluent Incyte Corporation (INCY) au consensus : Acheter. L'objectif de cours moyen est de 95,10 €, soit un potentiel de +11.06% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 61,90 € à 122,05 €.

Incyte Corporation : la thèse d'investissement en détail

Incyte Corporation (INCY) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Revenue is growing at a healthy 20.9% pace year-over-year, suggesting the business model continues to find new customers and pricing power. Earnings growth of 83.8% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. The combination of a 52.77% gross margin and 25.55% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat.

Valorisation en contexte

With a PEG ratio of 0.36, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 10.72x is meaningfully below the trailing 13.87x — analysts expect earnings to step up; the next earnings release is the test.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (9.83%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Incyte Corporation?

Compare top-rated brokers — low fees, trusted providers, fully regulated.